What is the role of pazopanib as second‑line therapy for adults with advanced or metastatic mixed‑grade soft‑tissue sarcoma who have progressed after anthracycline‑based chemotherapy and have adequate hepatic, renal, and cardiac function?

Pazopanib as Second-Line Therapy for Mixed-Grade Soft Tissue Sarcomas

Pazopanib 800 mg orally once daily is an established second-line treatment option for adults with advanced or metastatic non-adipocytic soft tissue sarcoma who have progressed after anthracycline-based chemotherapy, providing a median progression-free survival benefit of approximately 3 months compared to placebo. 1, 2, 3

FDA-Approved Indication and Critical Limitation

Pazopanib is FDA-approved for adults with advanced STS who have received prior chemotherapy 3. However, the efficacy has NOT been demonstrated in adipocytic (liposarcoma) subtypes or gastrointestinal stromal tumors 3. This is a critical exclusion—if your patient has liposarcoma, consider trabectedin or eribulin instead 2.

Evidence Base and Expected Outcomes

The pivotal EORTC 62072 phase III trial demonstrated:

• Median PFS: 4.6 months with pazopanib vs 1.6 months with placebo (P<0.0001) 1
• Overall survival showed a trend (12.5 vs 11 months) but was not statistically significant 1
• Quality of life measures neither improved nor declined with the PFS benefit 1

Both NCCN 2022 and ESMO-EURACAN 2021 guidelines classify pazopanib as a standard option for second-line and further-line therapy in non-adipogenic STS 1, 2. The ESMO guidelines assign it Level I evidence, Grade B recommendation with an ESMO-MCBS score of 3 2.

Histologic Subtype Considerations

Pazopanib demonstrates variable activity across histologic subtypes:

Best responses seen in:

• Synovial sarcoma (49% progression-free at 12 weeks) 4
• Leiomyosarcoma (44% progression-free at 12 weeks) 4
• Solitary fibrous tumor and extraskeletal myxoid chondrosarcoma 2

Poor/no activity in:

• Adipocytic sarcomas (only 26% progression-free at 12 weeks—trial closed early) 4
• GIST 3

Dosing Strategy and Practical Management

Standard FDA-approved dose: 800 mg orally once daily 3

However, real-world data suggests significant dose modifications are common:

• 40% of patients require dose reduction 5
• Median tolerated dose in some populations is 600 mg daily 5
• A reduced starting dose strategy (200-300 mg daily) may improve tolerability while maintaining efficacy 6

Administer without food (at least 1 hour before or 2 hours after meals) 3. Swallow tablets whole—do not crush, as this increases absorption and systemic exposure 3.

Critical Safety Monitoring Requirements

Hepatotoxicity (Black Box Warning)

Monitor liver function tests at baseline, regularly during treatment, and as clinically indicated 3:

• ALT 3-8× ULN (isolated): Continue with weekly monitoring
• ALT >8× ULN: Withhold until Grade ≤1, resume at reduced dose (400 mg) with weekly monitoring for 8 weeks
• ALT >3× ULN + bilirubin >2× ULN: Permanently discontinue 3

Cardiac Monitoring

Heart failure occurs in approximately 4% of patients 7. Risk factors include:

• Prior anthracycline exposure >225 mg/m² 7
• Age ≥60 years 7
• Baseline BNP ≥50 pg/mL 7

Obtain baseline LVEF and periodic monitoring in at-risk patients 3. Withhold for symptomatic or Grade 3 dysfunction; permanently discontinue for Grade 4 3.

Other Key Toxicities

Most common adverse events 1, 5:

• Hypertension (37%): Monitor blood pressure regularly
• Fatigue (51%)
• Diarrhea (33%)
• Nausea/vomiting (34%)
• Hand-foot syndrome (28%)
• Hypothyroidism (15%)

Dose Modifications for Hepatic Impairment

Moderate hepatic impairment: Reduce to 200 mg once daily 3. Pazopanib is contraindicated in severe hepatic impairment.

Alternative Second-Line Options for Comparison

When pazopanib is not suitable:

• Trabectedin: Preferred for liposarcoma and leiomyosarcoma (L-type sarcomas) 2
• Eribulin: Superior OS benefit in liposarcomas (7-month improvement) and leiomyosarcoma 2
• Gemcitabine/docetaxel: May have better response rates in certain subtypes (leiomyosarcoma, undifferentiated pleomorphic sarcoma, angiosarcoma) 2, 8

Key Clinical Pitfalls to Avoid

1. Do not use pazopanib for adipocytic sarcomas—efficacy not demonstrated 3, 4
2. Do not combine with strong CYP3A4 inhibitors or inducers without dose adjustment 3
3. Do not use in patients with recent arterial thromboembolic events (within 6 months) 3
4. Monitor for QT prolongation in at-risk patients; correct electrolyte abnormalities before initiating 3
5. Permanently discontinue for gastrointestinal perforation, arterial thromboembolism, or thrombotic microangiopathy 3